Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Positive Solid Tumors”

176 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 176 results

Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)UnknownNCT05115500
What this trial is testing

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Who this might be right for
CarcinomaSolid Tumor
Second Affiliated Hospital of Soochow University 55
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Early research (Phase 1)UnknownNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT07612891
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)Advanced Solid CancersMetastatic (Stage IV) Breast Cancer+2 more
Shenzhen Ionova Life Sciences Co., Ltd.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Not applicableLooking for participantsNCT06658951
What this trial is testing

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Who this might be right for
HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc. 30
Early research (Phase 1)Study completedNCT00927589
What this trial is testing

Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Who this might be right for
Solid Cancers
Genentech, Inc. 59
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Early research (Phase 1)UnknownNCT04189211
What this trial is testing

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

Who this might be right for
HER2-Positive Solid Tumors
Bio-Thera Solutions 30
Early research (Phase 1)UnknownNCT06254807
What this trial is testing

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positive
Carisma Therapeutics Inc 6
Very early researchLooking for participantsNCT05245058
What this trial is testing

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd 150
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178938
What this trial is testing

Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases

Who this might be right for
Solid TumorsHER2-positive Breast Cancer
MedSIR 10
Load More Results
201